# ScoreItem: Raz√£o androide/ginoide - mulher

**ID:** `019bf31d-2ef0-7276-b0d1-677ebd1fdf95`
**FullName:** Raz√£o androide/ginoide - mulher (Composi√ß√£o corporal - Atual - Medidas objetivas)
**Gender:** female

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 17 artigos
- Avg Similarity: 0.587

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7276-b0d1-677ebd1fdf95`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7276-b0d1-677ebd1fdf95",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Raz√£o androide/ginoide - mulher (Composi√ß√£o corporal - Atual - Medidas objetivas)
**G√™nero:** female

**30 chunks de 17 artigos (avg similarity: 0.587)**

### Chunk 1/30
**Article:** Mastologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.638

dos sintomas gerais a investigar em consulta, como dor mam√°ria e TPM intensa, que podem indicar predomin√¢ncia estrog√™nica.

## Objetivo:
N√£o h√° achados de exame f√≠sico de um paciente espec√≠fico. A abordagem objetiva descrita inclui:
- Avalia√ß√£o da composi√ß√£o corporal por bioimped√¢ncia ou densitometria de corpo total, identificando condi√ß√µes como sarcopenia em mulheres com peso normal.
- Solicita√ß√£o de exames laboratoriais para avaliar marcadores inflamat√≥rios e verificar se a paciente est√° metabolicamente doente ou em risco.

## Diagn√≥stico Prim√°rio:
- Avalia√ß√£o: Discuss√£o educacional sobre estratifica√ß√£o de risco para c√¢ncer de mama. 90% dos casos relacionam-se ao estilo de vida e 10% a fatores gen√©ticos conhecidos. Muta√ß√µes de alta penetr√¢ncia (ex.: BRCA1, BRCA2, TP53) aumentam significativamente o risco, por√©m s√£o raras. Epigen√©tica e estilo de vida s√£o cruciais e modific√°veis.

---

### Chunk 2/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** results | **Similarity:** 0.633

nd to be cor-related with the LH/FSH ratio in a nationally represen-tative sample of post-menopausal women in the USA (20). A study on 175 PCOS women in Iran showed that compared with non-obese women, obese PCOS women had higher odds of having a sonographic view of their polycystic ovaries using ultrasound examination (21).Results of this study could be explained by the relative-ly small sample size compared to previous studies. It is also possible that geographical or dietary variations play a role in the hormonal levels of PCOS women. Future research into the risk factors of PCOS in Saudi women is needed. I used a BMI cut o value of 25 kg/m2 which is dierent from some previous studies that considered the overweight population (BMI 25 to 29.9 kg/m2) to be classied in the normal BMI group.e signicant ndings in this study were the slight dierences between the study groups in terms of the T4 and testosterone levels (P>0.05).

---

### Chunk 3/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.621

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 4/30
**Article:** Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome (2019)
**Journal:** Scientific Reports
**Section:** other | **Similarity:** 0.616

genesisofPCOS(
5
)withhightestosterone(T)levelsbeinglinkedwithabdominalfatdistribution(
6
),glucoseintolerance(
5
),andinsulinresistance(
5
)aswellasovulatorydysfunction(
7
).BothandrostenedioneandTcontributetothetotalcirculatingandrogenpool.AlargecohortstudyofPCOS
womenshowedthatelevatedfreeTlevelsconferredincreasedmetabolicriskcomparedtoPCOSwomenwithisolatedincreasedandrostenedione(
8
).Normoandrogenicoligo-oranovulatorypatientswithpolycysticovariesoftenhaveamildermetabolicproÔ¨Ålethatmorecloselyresemblesthatofcontrolsubjects(
9
,
10
).Theclinicalindicationofhyperandrogenism,scoredbyFerrimanGallwey(FG),variesbyethnicity,sensitivityofthehairfolliclestoandrogens(
11
)aswellasthebiochemicallevelofcirculatingandrogens.Thus,FG-scorecorrelatesonlymodestlywith
totalserumT(
12
).Furthermore,hyperandrogenemia,butnothirsutism,wasfoundtobeanindependentpredictorofmetabolicsyndrome(MetS)presenceinPCOSpatients(
13
).GiventhatPCOSwomenalreadyhaveanunfavorablemetabolicproÔ¨Ålein
earlyadulthood,there

---

### Chunk 5/30
**Article:** Visceral Adiposity and Cardiometabolic Risk Factors in Postmenopausal Women: The Role of Estrogen Deficiency (2023)
**Journal:** Journal of Clinical Endocrinology & Metabolism
**Section:** abstract | **Similarity:** 0.612

Context: Menopause is associated with increased visceral adiposity and metabolic dysfunction. Objective: To evaluate the impact of estrogen deficiency on visceral fat accumulation and cardiometabolic markers. Design: Cross-sectional analysis of 2,456 postmenopausal women. Results: Postmenopausal women with WC ‚â•88 cm had 3.87-fold higher odds of hypertension (OR 3.87, 95% CI 2.91-5.15), 4.12-fold higher odds of metabolic syndrome, and significantly higher inflammatory markers (hs-CRP 5.8 vs 2.1 mg/L, p<0.001). Visceral adiposity was strongly correlated with insulin resistance (r=0.68), dyslipidemia, and increased CVD risk. Conclusion: Estrogen deficiency promotes visceral fat redistribution, leading to marked cardiometabolic deterioration in postmenopausal women.

---

### Chunk 6/30
**Article:** Mastologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** methods | **Similarity:** 0.601

; uso de medicamentos/suplementos; h√°bitos de vida (alimenta√ß√£o, exerc√≠cio, √°lcool, tabaco); sa√∫de intestinal; n√≠veis de estresse/ansiedade; rede de apoio.
   - Aten√ß√£o a sintomas de predomin√¢ncia estrog√™nica: dor mam√°ria, TPM intensa; lacunas de cuidado em pacientes com altera√ß√µes fibroc√≠sticas e cistos, frequentemente n√£o acolhidas apesar de sintomas de excesso de estrog√™nio circulante.
* **Avalia√ß√£o de composi√ß√£o corporal**
   - Prefer√™ncia por m√©todos al√©m da balan√ßa: bioimped√¢ncia (utilizada pela instrutora) ou densitometria de corpo total.
   - Observa√ß√£o de sarcopenia em mulheres com peso normal e desconhecimento da condi√ß√£o; necessidade de interven√ß√£o.
* **Marcadores laboratoriais e metabolicidade**
   - Solicitar marcadores inflamat√≥rios para identificar adoecimento metab√≥lico ou risco, e para monitorar evolu√ß√£o ap√≥s interven√ß√µes.

---

### Chunk 7/30
**Article:** Abdominal Obesity and Insulin Resistance in Women: Mechanisms and Clinical Implications (2020)
**Journal:** Diabetologia
**Section:** abstract | **Similarity:** 0.599

Aim: To review mechanisms linking abdominal obesity to insulin resistance in women. Methods: Narrative review of mechanistic and clinical studies. Results: Visceral adipose tissue (VAT) releases free fatty acids directly into portal circulation, leading to hepatic insulin resistance, increased gluconeogenesis, and dyslipidemia (elevated triglycerides, reduced HDL, small dense LDL). VAT also secretes pro-inflammatory adipokines (IL-6, TNF-Œ±, resistin) and reduced adiponectin. In women, estrogen deficiency during menopause exacerbates these pathways: estrogen normally promotes subcutaneous fat deposition and enhances insulin sensitivity via hepatic ER-Œ± receptors. Post-menopause, WC increases by 5-8 cm on average, with corresponding insulin resistance worsening. Clinical trials show that reducing WC by 5 cm improves insulin sensitivity by 15-20%. Conclusion: Targeting abdominal obesity is critical for metabolic health in women, especially post-menopause.

---

### Chunk 8/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** other | **Similarity:** 0.597

1988; (318): 558-562.8.  Richard SL RA. Androgen excess disorders. Danforth¬ís Ob-stetrics and Gynecology, 8th edition, Lippincott Williams & Wilkins, Philadelphia. ; Chapter 37. 2003: 663-672.9.  Johansson J, Stener-Victorin E. Polycystic ovary syndrome: ef-fect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med. 2013; 2013: 762615.10.  Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaf-farpasand F, Kazerooni Y. Eects of metformin plus simvas-tatin on polycystic ovary syndrome: a prospective, random-ized, double-blind, placebo-controlled study. Fertil Steril. 2010 Nov; 94(6): 2208-2213.11.  Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Es-cobar-Morreale HF, Futterweit W, et al. Assessment of Car-diovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consen-

Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs.

---

### Chunk 9/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.595

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health‚ÄìNational Heart, Lung, and Blood Institute (NHLBI)-sponsored Women‚Äôs
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985‚Äì4992
204. Christiansen JJ, Andersen NH, S√∏rensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, J√∏rgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426‚Äì433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240‚Äì245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207.

---

### Chunk 10/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.595

ntre pacientes.
- Estrat√©gia: evitar abordagem √∫nica; reconhecer interliga√ß√µes e tratar m√∫ltiplos eixos simultaneamente para romper o ciclo.
### 10. Diretrizes pr√°ticas para diagn√≥stico e manejo
- Diagn√≥stico precoce: triagem ativa; considerar dosagem de LH/FSH (rela√ß√£o frequentemente 2‚Äì3:1) para apoio diagn√≥stico/monitoramento.
- Reconhecer resist√™ncia √† insulina mesmo em mulheres magras, ainda que exames n√£o sejam conclusivos; avalia√ß√£o cl√≠nica justifica interven√ß√£o.
- Tratamento na raiz: controlar resist√™ncia √† insulina √© priorit√°rio; tratar hiperandrogenismo sem abordar resist√™ncia √† insulina √© insuficiente.
- Estilo de vida: dieta anti-inflamat√≥ria com menor carga de carboidratos; aumento de atividade f√≠sica (muscula√ß√£o, aer√≥bicos, HIIT) para melhorar sensibilidade √† insulina via massa muscular.
- Manejo da desbiose: avaliar hist√≥ria alimentar, uso de antibi√≥ticos, sinais de hiperpermeabilidade; interven√ß√µes nutricionais e de estilo de vida.

---

### Chunk 11/30
**Article:** Emagrecimento - Parte VII (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.593

; perfil mais estrog√™nico; maior aromatase e receptores de leptina; t√≠pico em mulheres; remov√≠vel por lipoaspira√ß√£o.
- Menopausa: redu√ß√£o do subcut√¢neo e aumento do visceral, com fen√≥tipo mais masculino.
- Implica√ß√µes de manejo: estrat√©gias de estilo de vida (dieta, treino, sono, estresse) s√£o chave para redu√ß√£o de gordura visceral.
### 5. M√∫sculo como √≥rg√£o end√≥crino: miocinas e benef√≠cios sist√™micos
- O m√∫sculo secreta miocinas anti-inflamat√≥rias, favorecendo homeostase sist√™mica; ganho de massa muscular combate resist√™ncia insul√≠nica e sarcopenia.
- Ferramentas: muscula√ß√£o, alimenta√ß√£o adequada, status hormonal e suplementos; estrat√©gias hormonais podem ser consideradas em casos selecionados.
- Exemplos de miocinas: IL-6 (no contexto do exerc√≠cio), irisin; refer√™ncia a Nature Reviews Rheumatology.
### 6.

---

### Chunk 12/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** other | **Similarity:** 0.591

2.75 ¬± 1.60.93T4 (mIU/L)1.18 ¬± 0.0351.26 ¬± 0.010.049*Testosterone (ng/ml)0.54 ¬± 0.180.38 ¬± 0.060.044*Data are presented as mean ¬± SD or n (%); ¬ÜMann-Whitney test or t-test for continuous variables and chi-square test for categorical variables; * statistically signiÔ¨ÅcantTable 1. The characteristics of the study population

Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women292ORIGINAL PAPER | MED ARCH. 2020 AUG; 74(4): 289-293hirsutism to be more present in obese than thin women (19). Nonetheless, our study failed to show any signi-cant correlation between BMI and the serum hormone levels of PCOS women including LH, FSH, and LH/FSH ratio.Obesity, insulin resistance, and dyslipidemia are PCOS-related morbidities and were found to be cor-related with the LH/FSH ratio in a nationally represen-tative sample of post-menopausal women in the USA (20).

---

### Chunk 13/30
**Article:** Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause (1)
**Journal:** Climacteric
**Section:** discussion | **Similarity:** 0.587

CLIA:Electrochemiluminescenceimmunoassay;FSH:Follicle-stimulatinghormone;HDL-c:High-densitylipoproteincholesterol;hsCRP:High-sensitivityC-reactiveproteintest;
HT:Hormonetherapy;LDL-c:Low-densitylipoproteincholesterol;
MPA:Medroxyprogesterone;NETA:Noretisterone;P:Progesterone;SBP:Systolicbloodpressure;SD:Standarddeviation;SPSS:StatisticalPackagefortheSocialSciences;usCRP:Ultra-sensitiveC-reactiveprotein;WC:Waist
circumference;WHR:Waist-to-hipratio.CompetinginterestsTheauthorsdeclarethattheyhavenocompetinginterests.Authors'contributionsGCandPMScontributedtoacquisitionofdata,analysisandinterpretationof
dataandmanuscriptreview.PMSconceivedanddesignedthestudy.Both
authorscontributedtotheanalysisandinterpretationofdata,draftingmanuscriptandfinalreview,andbothapprovedthefinalversionofthemanuscript.AcknowledgementsThisworkwassupportedbygrantsfromConselhoNacionaldeDesenvolvimentoCient√≠ficoeTecnol√≥gico(CNPqINCT573747/2008-3)andFundodeApoio√†PesquisadoHospitaldeCl√≠nicasdePortoAlegre(FIPE-
HCPA

---

### Chunk 14/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.584

o cr√¥nica.
    -   Lipoprote√≠na (a) elevada, um fator de risco gen√©tico pr√≥-tromb√≥tico e pr√≥-inflamat√≥rio.
    -   Desequil√≠brios hormonais (baixo estrog√™nio e testosterona), especialmente na menopausa.
-   **Diagn√≥stico Suspeito:** Nenhum no momento
## Plano:
-   **Prescri√ß√£o:** Inserir mais aqui
-   **Pr√≥ximos Passos/Exames:**
    -   O palestrante defende uma avalia√ß√£o abrangente que vai al√©m dos fatores de risco cl√°ssicos, incluindo:
    -   Dosagem das propor√ß√µes de √îmega-3 e √îmega-6 (√çndice √îmega-3).
    -   Medi√ß√£o do Horm√¥nio D (Vitamina D), com metas de n√≠veis √≥timos (ex: >80 ng/mL para cardiopatas, controlando com PTH).
    -   Curva glic√™mica e de insulina para detectar resist√™ncia √† insulina precocemente.
    -   Avalia√ß√£o da homociste√≠na.
    -   Medi√ß√£o da lipoprote√≠na (a).
    -   Avalia√ß√£o da rela√ß√£o ApoB/ApoA.
    -   Avalia√ß√£o dos n√≠veis hormonais (testosterona, estradiol, DHEA).

---

### Chunk 15/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.583

iation in HOMA-IR is not dependent on 
endogenous oestrogen or androgen levels in postmenopausal 
women. Clin Endocrinol (Oxf) 2012; 77: 541‚Äì47.47 Worsley R, Robinson PJ, Bell RJ, Moufarege A, Davis SR. Endogenous estrogen and androgen levels are not independent 
predictors of lipid levels in postmenopausal women. 
Menopause 2013; 20: 640‚Äì45.48 Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women‚Äôs Health Across 
the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010; 
18: 604‚Äì10.49 Pugeat M, Nader N, Hogeveen K, Raverot G, D√©chaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs 
and the metabolic syndrome. Mol Cell Endocrinol 2010; 316: 53‚Äì59.50 Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic 
sex hormone-binding globulin gene.

---

### Chunk 16/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 04 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.582

itos.
- Queda de cabelo acentuada.
- TPM muito intensa em mulheres.
## Objetivo:
Aula, n√£o consulta. Achados objetivos/patol√≥gicos gerais:
- Testosterona em homens diminui com a idade; n√≠veis <400 ng/dL s√£o considerados baixos.
- Baixa testosterona associada a maior ocorr√™ncia de obesidade, hipertens√£o, hiperlipidemia, alergias e diabetes.
- Alta preval√™ncia de hipogonadismo hipogonadotr√≥fico (falta de comando central) em homens obesos.
- Obesidade aumenta atividade da aromatase, resist√™ncia √† insulina e apneia do sono, levando a hipogonadismo hipotal√¢mico.
- Obesidade pode elevar a temperatura escrotal, piorar produ√ß√£o de testosterona e levar a oligospermia/azoospermia.
- Exames de sangue para horm√¥nios livres (ex.: testosterona livre) s√£o imprecisos no Brasil, pois laborat√≥rios calculam em vez de medir diretamente; ~80% dos horm√¥nios livres aderem √†s hem√°cias e s√£o removidos na centrifuga√ß√£o.

---

### Chunk 17/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.581

  65 years) were at 
greatest risk of subsequent cardiovascular disease.42 To be in the top Ô¨Å fth percentile, these women would have had 
extremely high concentrations of testosterone, such that 
polycystic ovary syndrome or another cause of excess 
androgens might be suspected.The association between low concentrations of testosterone and greater incidences of all-cause mortality 
and cardiovascular events, independent of traditional 
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

www.thelancet.com/diabetes-endocrinology   Published online September 8, 2015   http://dx.doi.org/10.1016/S2213-8587(15)00284-3 5Review
Number of patientsStudy sampleMean (SD) age or age rangeOutcome measuredResults for key endpointsAnkle brachial indexMaggio et al (2012)32502 postmenopausal 
womenPopulation based75¬∑6 years (7¬∑1)Ankle brachial index <0¬∑9Total testosterone (higher vs lower log testosterone), OR 2¬∑00 (95%

---

### Chunk 18/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.581

*
- Quase 60% das mulheres com SOP reportam insatisfa√ß√£o com os cuidados m√©dicos atuais.
- O dado sinaliza falhas em educa√ß√£o, rastreio precoce e personaliza√ß√£o terap√™utica.
**Achados Metab√≥licos e de Sinaliza√ß√£o sustentam o risco para diabetes tipo 2.**
- A SOP est√° associada √† diabetes mellitus tipo 2, ligada √† resist√™ncia √† insulina e hiperinsulinemia.
- Elementos da via de sinaliza√ß√£o da insulina (PI3K) e falhas na transloca√ß√£o do GLUT4 comprometem a capta√ß√£o de glicose, contribuindo para resist√™ncia √† insulina.
**Achados Adicionais**
- 17-hidroxiprogesterona √© citada no contexto de excesso androg√™nico e desequil√≠brio com androstenediona, como poss√≠vel marcador hormonal espec√≠fico.
- O risco de diabetes tipo 2 est√° aumentado em mulheres com SOP devido ao descontrole metab√≥lico associado.

---

### Chunk 19/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.578

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 20/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** discussion | **Similarity:** 0.577

did not signicantly cor-relate with any other serum hormone levels including the LH, FSH, prolactin, or TSH (all P>0.05).5. DISCUSSIONe results have shown that both normal BMI group and high BMI group had comparable LH/FSH ratio. In addition, study showed no signicant correlation be-tween the BMI and the LH/FSH ratio in the studied population.e normal gonadotrophin axis is disturbed in PCOS women, therefore LH levels increase, and FSH levels de-crease, leading to a reversal of LH/FSH ratio (16). e results are not concordant with the study of Lal et al. (17) who found signicant dierences between obese and non-obese women regarding LH, FSH, and LH/FSH ratio. Upon these ndings, they advised obese women who shared in the study to try to lose weight and change their lifestyle.A study by Alnakash et al. (18) has found no signif-icant statistical correlation between BMI and LH/FSH Ratio (18). Kiddy et al.

---

### Chunk 21/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** other | **Similarity:** 0.576

iovascular Disease in Women with the Polycystic Ovary Syndrome: A Consen-

Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women293ORIGINAL PAPER | MED ARCH. 2020 AUG; 74(4): 289-293sus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May; 95(5): 2038-2049.12.  Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Eects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Cross-over Trial. J Clin Endocrinol Metab. 2007 Feb; 92(2): 456-461.13.  Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Ef-fects of Simvastatin and Metformin on Polycystic Ovary Syn-drome after Six Months of Treatment. J Clin Endocrinol Me-tab. 2011 Nov; 96(11): 3493-3501.14.  Goyal M, Dawood AS. Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review. J Hum Re-prod Sci. 2017; 10(3): 154-161.15.

---

### Chunk 22/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** discussion | **Similarity:** 0.575

ormones (LH &amp; FSH) Associate With Clinical Symptoms Among Women With Polycystic Ovary Syndrome. Glob J Health Sci [Internet]. 2014 Sep 28;7(2). Available from: http://www.ccsenet.org/journal/index.php/gjhs/article/view/3933222.  Yuan C, Liu X, Mao Y, Diao F, Cui Y, Liu J. Polycystic ovary syndrome patients with high BMI tend to have functional dis-orders of androgen excess: a prospective study. J Biomed Res [Internet]. 2016 May 30;30(3):197¬ñ202. Available from: http://www.jbr-pub.org.cn/ch/reader/view_abstract.aspx?le_no=-jbr160306&ag=123.  Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J, et al. High yroid Stimulating Hormone Level Is Associated With Hy-perandrogenism in Euthyroid Polycystic Ovary Syndrome (PCOS) Women, Independent of Age, BMI, and yroid Au-toimmunity: A Cross-Sectional Analysis. Front Endocrinol (Lausanne) [Internet]. 2019 Apr 10;10. Available from: https://www.frontiersin.org/article/10.3389/fendo.2019.00222/full24.  Yu Q, Wang J-B.

---

### Chunk 23/30
**Article:** Resist√™ncia Insul√≠nica (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.570

rila√ß√£o em serina e dislipidemias.
- Lipodistrofias (parciais/total) tamb√©m predisponentes; adiponectina como fator protetor (quando elevada).
## Rim, SNC e Cora√ß√£o: Consequ√™ncias Sist√™micas
- Rim: hiperinsulinemia aumenta reabsor√ß√£o de s√≥dio (SRAA, SNA); hipertens√£o frequentemente precede DM; risco de arritmias; gordura perirrenal.
- SNC: menor insulina intracerebral reduz efeito anorex√≠geno, aumenta apetite, prejudica mem√≥ria (hipocampo), eleva beta-amiloide e neuroinflama√ß√£o.
- Cora√ß√£o: aumento de gordura epic√°rdica, inflama√ß√£o, disfun√ß√£o endotelial, comprometimento microcirculat√≥rio e aterog√™nese; alto impacto por densidade mitocondrial.
## Sinais Cl√≠nicos e Medidas Antropom√©tricas
- Circunfer√™ncia abdominal: homens sul-americanos >90 cm, mulheres >80 cm (ajustar por etnia; japoneses possuem cortes distintos).
- Rela√ß√£o cintura-quadril: √∫til em alguns contextos.

---

### Chunk 24/30
**Article:** Follicle Stimulating Hormone (LH:FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women (2020)
**Journal:** Med Arch
**Section:** introduction | **Similarity:** 0.568

Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women289ORIGINAL PAPER | MED ARCH. 2020 AUG; 74(4): 289-293
Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese WomenZaheera SaadiaABSTRACTIntroduction: Polycystic Ovary Syndrome (PCOS), the most common endocrinological prob-lem among women in the reproductive age, is characterized by chronic ovulatory dysfunction, hyperandrogenism, and raised Luteinizing hormone : Follicle Stimulating Hormone (LH:FSH) ratio. Obesity and insulin resistance have been linked to PCOS. However, there is recently a growing population of thin, lean women who are diagnosed with PCOS. Aim: This study aimed to compare normal and high Body mass index (BMI) women with PCOS and to investigate the correlation between BMI and LH/FSH ratio.

---

### Chunk 25/30
**Article:** Waist Circumference Thresholds and Cardiovascular Outcomes in European Women: The EPIC-CVD Study (2019)
**Journal:** European Heart Journal
**Section:** abstract | **Similarity:** 0.565

Aims: To validate WC thresholds for CVD risk in European women. Methods: Pooled analysis of 125,678 women from 23 European cohorts (median follow-up 10.7 years). Results: WC ‚â•80 cm was associated with 1.6-fold increased CVD risk (HR 1.62, 95% CI 1.48-1.78), while WC ‚â•88 cm conferred 2.4-fold risk (HR 2.41, 95% CI 2.18-2.67). Each 1-cm WC increment increased CVD risk by 3% (HR 1.03 per cm). Women with WC ‚â•88 cm and low HDL (<50 mg/dL) had particularly high risk (HR 4.87). Importantly, normal-weight women (BMI <25) with WC ‚â•80 cm still had elevated risk (HR 1.83), highlighting the importance of central obesity independent of total body weight. Conclusion: WC should be measured routinely in all women regardless of BMI.

---

### Chunk 26/30
**Article:** Regional Adiposity and Risk of Cardiovascular Disease in Women: The Framingham Heart Study (2021)
**Journal:** Circulation
**Section:** abstract | **Similarity:** 0.564

Background: Abdominal visceral adipose tissue (VAT) confers greater cardiovascular risk than subcutaneous fat. Methods: Prospective follow-up of 3,001 women (mean age 51 years) for median 12.3 years. VAT was quantified by CT imaging. Results: Women in the highest VAT quartile (‚â•150 cm¬≤) had 3.2-fold increased risk of coronary artery disease (HR 3.24, 95% CI 2.17-4.83) independent of BMI. WC ‚â•88 cm correlated with VAT ‚â•100 cm¬≤ (r=0.78). Each 1-SD increase in VAT was associated with 45% higher CVD risk, 58% higher diabetes risk, and 32% higher all-cause mortality. Inflammatory markers (IL-6, TNF-Œ±) were elevated in high VAT groups. Conclusion: Visceral adiposity measured by WC is a powerful independent predictor of cardiovascular outcomes in women.

---

### Chunk 27/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.560

double-blind, placebo-controlled study. 
J Clin Endocrinol Metab 2006; 91: 1683‚Äì90.80 Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insu  ciency: results of a 
three-year randomized controlled trial of physiological transdermal 
estradiol and testosterone replacement. 
J Clin Endocrinol Metab 2014; 99: 3418‚Äì26.81 Dobs AS, Nguyen T, Pace C, Roberts CP. Di erential e ects of oral estrogen versus oral estrogen-androgen replacement therapy on 
body composition in postmenopausal women. 
J Clin Endocrinol Metab 2002; 87: 1509‚Äì16.82 Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133‚Äì40.83 Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes 2011; 18: 198‚Äì203.84 Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast 
cancer.

---

### Chunk 28/30
**Article:** Testosterone in women‚Äîthe clinical significance (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.560

reduces liver fat is associated with 
an increase in SHBG, an eÔ¨Ä ect that seems to be independent of 
insulin resistance.44,45 In postmenopausal women, the free androgen index (FAI, calculated as total 
testosterone √∑ SHBG √ó 100), but not total testosterone, is 
associated with the metabolic syndrome and an increased risk 
of cardiovascular disease.51,52 Thus, concentrations of SHBG but not testosterone explain the association between FAI and free 
fraction of testosterone‚Äîand other sex steroids‚Äîin plasma, but 
low concentrations of SHBG are an independent risk factor for 
insulin resistance, type 2 diabetes, and adverse lipid proÔ¨Å le in young women and women at midlife.44,46,47
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

www.thelancet.com/diabetes-endocrinology   Published online September 8, 2015   http://dx.doi.org/10.1016/S2213-8587(15)00284-3 7Review
and have anti-inÔ¨Ç ammatory action

---

### Chunk 29/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.559

06. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207. Mohan PF, Ihnen JS, Levin BE, Cleary MP. Effects of dehydroepiandrosterone
treatment in rats with diet-induced obesity. J Nutr 1990;120:1103‚Äì1114
208. Hansen PA, Han DH, Nolte LA, Chen M, Holloszy JO.DHEA protects against visceral
obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol
1997;273:R1704‚ÄìR1708
209. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life
women: The Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005;
90:4836‚Äì4845
210. Corona G, Rastrelli G, Giagulli VA, Sila A, Sforza A, Forti G, Mannucci E, Maggi M.
Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-
controlled trials. J Clin Endocrinol Metab 2013 ;98:3615-26
211. Steinberg, H. O.
,
 
Chaker, H.
,
 
Leaming, R.

---

### Chunk 30/30
**Article:** Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome (2020)
**Journal:** International Journal of Molecular Sciences
**Section:** discussion | **Similarity:** 0.559

rinology2015,156,4571‚Äì4581.[CrossRef]79.Mueller,N.T.;Liu,T.;Mitchel,E.B.;Yates,K.P.;Suzuki,A.;Behling,C.;Lavine,J.E.SexHormoneRelationstoHistologicSeverityofPediatricNonalcoholicFattyLiverDisease.J.Clin.Endocrinol.Metab.2020,105,dgaa574.[CrossRef][PubMed]80.Lim,S.S.;Kakoly,N.S.;Tan,J.W.J.;Fitzgerald,G.;BahriKhomami,M.;Joham,A.E.;Cooray,S.D.;Misso,M.L.;Norman,R.J.;Harrison,C.L.;etal.Metabolicsyndromeinpolycysticovarysyndrome:Asystematicreview,meta-analysisandmeta-regression.Obes.Rev.2019,20,339‚Äì352.[CrossRef]81.Moran,L.J.;Teede,H.J.;Noakes,M.;Clifton,P.M.;Norman,R.J.;Wittert,G.A.Sexhormonebindingglobulin,butnottestosterone,isassociatedwiththemetabolicsyndromeinoverweightandobesewomenwithpolycysticovarysyndrome.J.Endocrinol.Invest.2013,36,1004‚Äì1010.82.Januszewski,M.;Issat,T.;Jakimiuk,A.A.;Santor-Zaczynska,M.;Jakimiuk,A.J.MetabolicandhormonaleÔøΩectsofacombinedMyo-inositolandd-chiro-inositoltherapyonpatientswithpolycysticovarysyndrome(PCOS).Ginekol.Pol.2019,90,7‚Äì10.[CrossRef]83.De

---

